Journal
RHEUMATOLOGY
Volume 55, Issue 11, Pages 2033-2039Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kew314
Keywords
rheumatoid arthritis; cancer; anti-TNF; rituximab; cohort study
Categories
Funding
- BSR Executive of the BSR Registers and Research Committee
- BSRBR-RA Project Team in London
- Abbott Laboratories
- Pfizer
- Roche
- UCB Pharma
- BSR
- University of Manchester
- EULAR Scientific Training Bursary
- Spanish Foundation of Rheumatology (FER)
- MRC Clinician Scientist Fellowship
- National Institute for Health Research [NF-SI-0510-10211] Funding Source: researchfish
- Versus Arthritis [20747] Funding Source: researchfish
Ask authors/readers for more resources
Objective. To explore the influence of TNF inhibitor (TNFi) therapy and rituximab (RTX) upon the incidence of cancer in patients with RA and prior malignancy. Methods. The study population comprised RA subjects with a prior malignancy reported to the UK national cancer registers, recruited to the British Society for Rheumatology Biologics Register from 2001 to 2013. We compared rates of first incident malignancy in a TNFi cohort, RTX cohort and synthetic DMARDs (sDMARD) cohort. Results. We identified 425 patients with a prior malignancy from 18 000 RA patients in the study. Of these, 101 patients developed a new malignancy. The rates of incident malignancy were 33.3 events/1000 person-years (py) in the TNFi cohort, 24.7 events/1000 py in the RTX cohort and 53.8 events/1000 py in the sDMARD cohort. The age- and gender-adjusted hazard ratio was 0.55 (95% CI: 0.35, 0.86) for the TNFi cohort and 0.43 (95% CI: 0.10, 1.80) for the RTX cohort in comparison with the sDMARDs cohort. The 17.0% of patients in the sDMARDs cohort had a recurrence of the same cancer in comparison with the 12.8% and the 4.3% in the TNFi and RTX cohorts, respectively. Conclusions. Although numbers are still low, it seems that patients with RA and prior malignancy selected to receive either a TNFi or RTX in the UK do not have an increased risk of future incident malignancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available